Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Active device tagging to excel in burgeoning global RFID market

This article was originally published in Clinica

Executive Summary

3,500 new radiofrequency identification (RFID) tagging projects, of which healthcare is a key area, in 109 countries were recorded by sector analysts IDTechEx in 2007. The US and China are said to be vying for the world market leadership, at $1.3bn apiece, but the two countries diverge hugely in their use of passive and active tagging, according to IDTechEx chairman Peter Harrop. The US features predominantly the latter, such as used in real-time location systems (RTLS) for medical equipment and devices. "By contrast, China has been pre-eminent in using passive tags...However, [active] RFID is a government priority" in terms of both increasing the supply of the technology and using it to improve the competitiveness of China, Dr Harrop believes. Active RFID, which is expected to grow from 12% of the market to 26% over the next decade, is the subject of the conference "Active RFID, RTLS and sensor networks", which takes place in Dallas, Texas, on November 5-6. See

You may also be interested in...

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications

Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts